ALEMBIC PHARMACEUTICALS
LIMITED
RESULTS FOR Q1 FY 2015
JUNE 2014
ALEMBIC PHARMA has done well in Q1 FY
15 ending June 2014.
Net Sales have gone by 7% QoQ and 16%
YoY.
Net Profit has gone up by 5.51% QoQ
and 38.66% YoY. Thus, both sequentially and Year on Year, Alembic Pharma has scored
well in Q1 FY 15.
The EBITDA margins also have improved
to 19.5% from 16.7% YoY.
Totally, 35 ANDA applications have
received approvals so far – including 3 in Q1.
Total ANDA filings are 64 including 3
in Q1.
Alembic’s state of the Art
Manufacturing facilities are approved by regulatory authorities all over the world including US FDA.
Alembic Pharma is progressing impressively
in terms of both sales and Net Profits.
TABLE OF RESULTS
|
Alembic Pharma
|
Q1FY15
|
Q4FY14
|
Dif%QoQ
|
Q1FY14
|
Dif%YoY
|
FY14
|
|
Net Sales
|
493.65
|
463.33
|
6.54
|
426.59
|
15.72
|
1860.7
|
|
Net Income
|
494.28
|
464.03
|
6.52
|
427.16
|
15.71
|
1863.21
|
|
OPT
|
96.67
|
91.29
|
5.89
|
71.48
|
35.24
|
357.71
|
|
PBT
|
84.93
|
80.78
|
5.14
|
60.5
|
40.38
|
310.5
|
|
NPT
|
64.67
|
61.29
|
5.51
|
46.64
|
38.66
|
235.5
|
|
EPS
|
3.43
|
3.25
|
5.54
|
2.47
|
38.87
|
12.49
|
|
EQ(FV Rs.2)
|
37.7
|
* * * E N D * * *
No comments:
Post a Comment